Clinical and pharmacological group: & nbsp

Anticoagulants

Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

ONLS

АТХ:

B.01.A.E.04   Melagatran

Pharmacodynamics:

Competitively and reversibly inhibits free and bound α-thrombin, which converts in the coagulation cascade the conversion of fibrinogen into fibrin. This prevents thrombus formation.

Pharmacokinetics:

After subcutaneous administration, the maximum concentration in the blood plasma is reached after 30 minutes. Not exposed to metabolism.

T ½ is 2-3 hours. Elimination by the kidneys in unchanged form.

Indications:

It is used for the prophylaxis of thromboembolic complications for patients who underwent a planned operation of knee or hip joint endoprotezisation.

IX.I26-I28.I26   Pulmonary embolism

IX.I70-I79.I74   Embolism and thrombosis of the arteries

IX.I80-I89.I82   Embolism and thrombosis of other veins

Contraindications:

Chronic renal and hepatic insufficiency, bleeding, age under 18, pregnancy and lactation, individual intolerance.

Carefully:

Patients older than 75 years with a body weight below 50 kg.

Pregnancy and lactation:

Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.

Dosing and Administration:

Subcutaneously, 3 mg not earlier than 4 hours and no later than 8 hours after the operation. Then 2 times / day for 1-2 days.

The highest daily dose: 6 mg.

The highest single dose: 3 mg.

Side effects:

Central and peripheral nervous system: headache, dizziness.

The cardiovascular system: tachycardia or bradycardia, hypertension or hypotension.

Hemopoietic system: anemia, bleeding.

Digestive system: indigestion, diarrhea, constipation.

Dermatological reactions: a rash.

urinary system: retention of urine.

Allergic reactions.

Overdose:

Cases of overdose are not described.

Treatment is symptomatic.

Interaction:

With simultaneous use with erythromycin, clarithromycin, azithromycin, antagonists K, heparin, acetylsalicylic acid, cyclosporine increases the risk of bleeding.

Special instructions:

The drug is not used for intramuscular injection.

Instructions
Up